Gaster B, Holroyd J
Department of Medicine, University of Washington, Seattle, USA.
Arch Intern Med. 2000 Jan 24;160(2):152-6. doi: 10.1001/archinte.160.2.152.
To address whether St John's wort is useful for the treatment of depression we attempted to retrieve all English-language articles with data on the efficacy, safety, and availability of St John's wort. Randomized, controlled, double-blind trials were selected and assessed for methodological quality using a standardized checklist, and data on pharmacology, cost, regulation, and safety were extracted. Eight studies were identified, found to be of generally good methodological quality, and determined to provide a modest amount of data to suggest that St John's wort is more effective than placebo in the treatment of mild to moderate depression. The absolute increased response rate with the use of St John's wort ranged from 23% to 55% higher than with placebo, but ranged from 6% to 18% lower compared with tricyclic antidepressants. More data are required to assess both its use in severe depression and its efficacy compared with other antidepressants. Rates of side effects were low. As a dietary supplement, St John's wort is currently largely unregulated, but the Food and Drug Administration is reviewing plans to tighten its regulatory oversight.
为了探讨圣约翰草是否对治疗抑郁症有效，我们试图检索所有包含圣约翰草功效、安全性及可得性数据的英文文章。我们选取了随机对照双盲试验，并使用标准化清单对其方法学质量进行评估，同时提取了有关药理学、成本、监管和安全性的数据。共识别出八项研究，发现这些研究的方法学质量总体良好，并确定它们提供了一定的数据，表明圣约翰草在治疗轻至中度抑郁症方面比安慰剂更有效。使用圣约翰草的绝对反应率提高幅度比安慰剂高23%至55%，但与三环类抗抑郁药相比则低6%至18%。需要更多数据来评估其在重度抑郁症中的应用以及与其他抗抑郁药相比的疗效。副作用发生率较低。作为一种膳食补充剂，圣约翰草目前在很大程度上不受监管，但美国食品药品监督管理局正在审查加强其监管监督的计划。
